{"count": 9, "results": [{"_id": "32526874", "pmid": 32526874, "pmcid": "PMC7356968", "title": "Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands", "journal": "Pharmaceutics", "authors": ["Kanellopoulos P", "Kaloudi A", "Jong M", "Krenning EP", "Nock BA", "Maina T"], "date": "2020-06-09T00:00:00Z", "doi": "10.3390/pharmaceutics12060528", "meta_date_publication": "2020 Jun 9", "meta_volume": "12", "meta_issue": "6", "meta_pages": "", "score": 50250.203, "text_hl": "Intense uptake is seen on kidneys and @<m>DISEASE_Neoplasms</m> @DISEASE_MESH:D009369 @@@tumor@@@. In (a) high uptake is observed in the kidneys and in (b) a notable increase in the @<m>DISEASE_Neoplasms</m> @DISEASE_MESH:D009369 @@@tumor@@@ uptake has resulted after treatment of @SPECIES_10090 @@@mice@@@ with @CHEMICAL_phosphoramidon @CHEMICAL_MESH:C008890 @@@PA@@@+@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lis@@@. ", "citations": {"NLM": "Kanellopoulos P, Kaloudi A, Jong M, Krenning EP, Nock BA, Maina T. Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands Pharmaceutics. 2020 Jun 9;12(6):. PMID: 32526874", "BibTeX": "@article{32526874, title={Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands}, author={Kanellopoulos P and Kaloudi A and Jong M and Krenning EP and Nock BA and Maina T}, journal={Pharmaceutics}, volume={12}, number={6}}"}}, {"_id": "33114537", "pmid": 33114537, "pmcid": "PMC7663772", "title": "Optimizing the Profile of [99mTc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors", "journal": "Int J Mol Sci", "authors": ["Kanellopoulos P", "Nock BA", "Krenning EP", "Maina T"], "date": "2020-10-26T00:00:00Z", "doi": "10.3390/ijms21217926", "meta_date_publication": "2020 Oct 26", "meta_volume": "21", "meta_issue": "21", "meta_pages": "", "score": 50248.363, "text_hl": "However, in the @CHEMICAL_sacubitril_and_valsartan_sodium_hydrate_drug_combination @CHEMICAL_MESH:C549068 @@@Entresto@@@ + @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lis@@@ treated @SPECIES_10090 @@@mice@@@, the @<m>DISEASE_Neoplasms</m> @DISEASE_MESH:D009369 @@@tumor@@@-to-kidneys ratio was clearly superior. ", "citations": {"NLM": "Kanellopoulos P, Nock BA, Krenning EP, Maina T. Optimizing the Profile of [99mTc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors Int J Mol Sci. 2020 Oct 26;21(21):. PMID: 33114537", "BibTeX": "@article{33114537, title={Optimizing the Profile of [99mTc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors}, author={Kanellopoulos P and Nock BA and Krenning EP and Maina T}, journal={Int J Mol Sci}, volume={21}, number={21}}"}}, {"_id": "38045916", "pmid": 38045916, "pmcid": "PMC10691487", "title": "The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT-Medicare linked data", "journal": "Front Cardiovasc Med", "authors": ["Du XL", "Martinez J", "Yamal JM", "Simpson LM", "Davis BR"], "date": "2023-11-17T00:00:00Z", "doi": "10.3389/fcvm.2023.1272385", "meta_date_publication": "2023", "meta_volume": "10", "meta_issue": "", "meta_pages": "1272385", "score": 50247.37, "text_hl": "After adjusting for socio-demographics, comorbidities, and other potential confounding factors in the time-to-event Cox models (Table 3), the 6-year risk of @<m>DISEASE_Neoplasms</m> @DISEASE_MESH:D009369 @@@cancer@@@ was statistically significantly higher for @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ vs. ", "citations": {"NLM": "Du XL, Martinez J, Yamal JM, Simpson LM, Davis BR. The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT-Medicare linked data Front Cardiovasc Med. 2023;10():1272385. PMID: 38045916", "BibTeX": "@article{38045916, title={The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT-Medicare linked data}, author={Du XL and Martinez J and Yamal JM and Simpson LM and Davis BR}, journal={Front Cardiovasc Med}, volume={10}, pages={1272385}}"}}, {"_id": "39282930", "pmid": 39282930, "title": "Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors.", "journal": "Clin Sci (Lond)", "authors": ["Camarda ND", "Lu Q", "Meola DM", "Man JJ", "Song Z", "Travers RJ", "Lopez KE", "Powers SN", "Papanastasiou M", "DeRuff KC", "Mullahoo J", "Egri SB", "Davison D", "Sebastiani P", "Eblen ST", "Buchsbaum R", "Huggins GS", "London CA", "Jaffe JD", "Upshaw JN", "Yang VK", "Jaffe IZ"], "date": "2024-09-18T00:00:00Z", "doi": "10.1042/CS20240537", "meta_date_publication": "2024 Sep 18", "meta_volume": "138", "meta_issue": "18", "meta_pages": "1131-1150", "score": 50242.37, "text_hl": "@SPECIES_9615 @@@Canine@@@ @<m>DISEASE_Neoplasms</m> @DISEASE_MESH:D009369 @@@cancer@@@ @SPECIES_9606 @@@patients@@@ with VEGFRi-induced-@DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ were randomized to @CHEMICAL_Doxazosin @CHEMICAL_MESH:D017292 @@@doxazosin@@@ or @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ and both agents significantly decreased SBP. ", "citations": {"NLM": "Camarda ND, Lu Q, Meola DM, Man JJ, Song Z, Travers RJ, Lopez KE, Powers SN, Papanastasiou M, DeRuff KC, Mullahoo J, Egri SB, Davison D, Sebastiani P, Eblen ST, Buchsbaum R, Huggins GS, London CA, Jaffe JD, Upshaw JN, Yang VK, Jaffe IZ. Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors. Clin Sci (Lond). 2024 Sep 18;138(18):1131-1150. PMID: 39282930", "BibTeX": "@article{39282930, title={Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors.}, author={Camarda ND and Lu Q and Meola DM and Man JJ and Song Z and Travers RJ and Lopez KE and Powers SN and Papanastasiou M and DeRuff KC and Mullahoo J and Egri SB and Davison D and Sebastiani P and Eblen ST and Buchsbaum R and Huggins GS and London CA and Jaffe JD and Upshaw JN and Yang VK and Jaffe IZ}, journal={Clin Sci (Lond)}, volume={138}, number={18}, pages={1131-1150}}"}}, {"_id": "35847929", "pmid": 35847929, "pmcid": "PMC9283643", "title": "Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab", "journal": "Front Oncol", "authors": ["Ren T", "Jia H", "Wu Q", "Zhang Y", "Ma Q", "Yao D", "Gao X", "Xie D", "Xu Z", "Zhao Q", "Zhang Y"], "date": "2022-07-01T00:00:00Z", "doi": "10.3389/fonc.2022.829059", "meta_date_publication": "2022", "meta_volume": "12", "meta_issue": "", "meta_pages": "829059", "score": 50239.44, "text_hl": "These findings suggest that @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lis@@@ prevents the fibrotic infiltration of @<m>DISEASE_Neoplasms</m> @DISEASE_MESH:D009369 @@@tumor@@@ tissues (Figure 3F).", "citations": {"NLM": "Ren T, Jia H, Wu Q, Zhang Y, Ma Q, Yao D, Gao X, Xie D, Xu Z, Zhao Q, Zhang Y. Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab Front Oncol. 2022;12():829059. PMID: 35847929", "BibTeX": "@article{35847929, title={Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab}, author={Ren T and Jia H and Wu Q and Zhang Y and Ma Q and Yao D and Gao X and Xie D and Xu Z and Zhao Q and Zhang Y}, journal={Front Oncol}, volume={12}, pages={829059}}"}}, {"_id": "37354687", "pmid": 37354687, "title": "THE NITROSAMINE CONTAMINATION IN BETA BLOCKERS (BISOPROLOL/METOPROLOL), ACE INHIBITORS (LISINOPRIL/PERINDOPRIL), THIAZIDES DIURETICS (HCT), CALCIUM CHANNEL BLOCKERS (AMLODIPINE/FELODIPINE), SARTANS (CANDESARTAN) AND THE SUBSEQUENT SKIN CANCER DEVELOPMENT AND PROGRESSION: APOCALYPSE NOW.", "journal": "Georgian Med News", "authors": ["Tchernev G"], "date": "2023-04-01T00:00:00Z", "meta_date_publication": "2023 Apr", "meta_volume": "", "meta_issue": "337", "meta_pages": "138-145", "score": 50231.27, "text_hl": "For the first time in the scientific literature, the contributory pro-@DISEASE_Precancerous_Conditions @DISEASE_MESH:D011230 @@@carcinogenic@@@ role of another potentially @CHEMICAL_Nitrosamines @CHEMICAL_MESH:D009602 @@@nitrosamine@@@-contaminated ACE inhibitor- @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@ , as well as that of @CHEMICAL_candesartan @CHEMICAL_MESH:C081643 @@@candesartan@@@: in the development of @<m>DISEASE_Neoplasms</m> @DISEASE_MESH:D009369 @@@keratinocytic cancer@@@ is also discussed. ", "citations": {"NLM": "Tchernev G. THE NITROSAMINE CONTAMINATION IN BETA BLOCKERS (BISOPROLOL/METOPROLOL), ACE INHIBITORS (LISINOPRIL/PERINDOPRIL), THIAZIDES DIURETICS (HCT), CALCIUM CHANNEL BLOCKERS (AMLODIPINE/FELODIPINE), SARTANS (CANDESARTAN) AND THE SUBSEQUENT SKIN CANCER DEVELOPMENT AND PROGRESSION: APOCALYPSE NOW. Georgian Med News. 2023 Apr;(337):138-145. PMID: 37354687", "BibTeX": "@article{37354687, title={THE NITROSAMINE CONTAMINATION IN BETA BLOCKERS (BISOPROLOL/METOPROLOL), ACE INHIBITORS (LISINOPRIL/PERINDOPRIL), THIAZIDES DIURETICS (HCT), CALCIUM CHANNEL BLOCKERS (AMLODIPINE/FELODIPINE), SARTANS (CANDESARTAN) AND THE SUBSEQUENT SKIN CANCER DEVELOPMENT AND PROGRESSION: APOCALYPSE NOW.}, author={Tchernev G}, journal={Georgian Med News}, number={337}, pages={138-145}}"}}, {"_id": "28497361", "pmid": 28497361, "title": "Design and characterization of lisinopril-loaded superparamagnetic nanoparticles as a new contrast agent for in vitro, in vivo MRI imaging, diagnose the tumors and drug delivery system.", "journal": "J Mater Sci Mater Med", "authors": ["Abbasi Pour S", "Shaterian HR"], "date": "2017-06-01T00:00:00Z", "doi": "10.1007/s10856-017-5900-0", "meta_date_publication": "2017 Jun", "meta_volume": "28", "meta_issue": "6", "meta_pages": "91", "score": 50055.742, "text_hl": "Design and characterization of @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@-loaded superparamagnetic nanoparticles as a new contrast agent for in vitro, in vivo MRI imaging, diagnose the @<m>DISEASE_Neoplasms</m> @DISEASE_MESH:D009369 @@@tumors@@@ and drug delivery system.", "citations": {"NLM": "Abbasi Pour S, Shaterian HR. Design and characterization of lisinopril-loaded superparamagnetic nanoparticles as a new contrast agent for in vitro, in vivo MRI imaging, diagnose the tumors and drug delivery system. J Mater Sci Mater Med. 2017 Jun;28(6):91. PMID: 28497361", "BibTeX": "@article{28497361, title={Design and characterization of lisinopril-loaded superparamagnetic nanoparticles as a new contrast agent for in vitro, in vivo MRI imaging, diagnose the tumors and drug delivery system.}, author={Abbasi Pour S and Shaterian HR}, journal={J Mater Sci Mater Med}, volume={28}, number={6}, pages={91}}"}}, {"_id": "30430227", "pmid": 30430227, "title": "Pharmacokinetics of liposomal curcumin (Lipocurc ) infusion: effect of co-medication in cancer patients and comparison with healthy individuals.", "journal": "Cancer Chemother Pharmacol", "authors": ["Bolger GT", "Licollari A", "Tan A", "Greil R", "Vcelar B", "Greil-Ressler S", "Weiss L", "Schönlieb C", "Magnes T", "Radl B", "Majeed M", "Sordillo PP"], "date": "2019-02-01T00:00:00Z", "doi": "10.1007/s00280-018-3730-5", "meta_date_publication": "2019 Feb", "meta_volume": "83", "meta_issue": "2", "meta_pages": "265-275", "score": 50034.42, "text_hl": "RESULTS: Of 44 co-medications studied, three medications targeting the @GENE_REN @GENE_5972 @@@renin@@@-angiotensin system, @<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@Lisinopril@@@, @CHEMICAL_Ramipril @CHEMICAL_MESH:D017257 @@@Ramipril@@@, and @CHEMICAL_Valsartan @CHEMICAL_MESH:D000068756 @@@Valsartan@@@ elevated plasma levels of @CHEMICAL_Curcumin @CHEMICAL_MESH:D003474 @@@curcumin@@@ and @CHEMICAL_tetrahydrocurcumin @CHEMICAL_MESH:C096277 @@@THC@@@ in three @<m>DISEASE_Neoplasms</m> @DISEASE_MESH:D009369 @@@cancer@@@ @SPECIES_9606 @@@patients@@@ infused with Lipocurc . ", "citations": {"NLM": "Bolger GT, Licollari A, Tan A, Greil R, Vcelar B, Greil-Ressler S, Weiss L, Schönlieb C, Magnes T, Radl B, Majeed M, Sordillo PP. Pharmacokinetics of liposomal curcumin (Lipocurc ) infusion: effect of co-medication in cancer patients and comparison with healthy individuals. Cancer Chemother Pharmacol. 2019 Feb;83(2):265-275. PMID: 30430227", "BibTeX": "@article{30430227, title={Pharmacokinetics of liposomal curcumin (Lipocurc ) infusion: effect of co-medication in cancer patients and comparison with healthy individuals.}, author={Bolger GT and Licollari A and Tan A and Greil R and Vcelar B and Greil-Ressler S and Weiss L and Schönlieb C and Magnes T and Radl B and Majeed M and Sordillo PP}, journal={Cancer Chemother Pharmacol}, volume={83}, number={2}, pages={265-275}}"}}, {"_id": "28600474", "pmid": 28600474, "title": "Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.", "journal": "Clin Cancer Res", "authors": ["Liu H", "Naxerova K", "Pinter M", "Incio J", "Lee H", "Shigeta K", "Ho WW", "Crain JA", "Jacobson A", "Michelakos T", "Dias-Santos D", "Zanconato A", "Hong TS", "Clark JW", "Murphy JE", "Ryan DP", "Deshpande V", "Lillemoe KD", "Fernandez-Del Castillo C", "Downes M", "Evans RM", "Michaelson J", "Ferrone CR", "Boucher Y", "Jain RK"], "date": "2017-10-01T00:00:00Z", "doi": "10.1158/1078-0432.CCR-17-0256", "meta_date_publication": "2017 Oct 1", "meta_volume": "23", "meta_issue": "19", "meta_pages": "5959-5969", "score": 50028.41, "text_hl": "RNA-Seq analysis revealed in @<m>DISEASE_Neoplasms</m> @DISEASE_MESH:D009369 @@@tumors@@@ of ASI users (@<m>CHEMICAL_Lisinopril</m> @CHEMICAL_MESH:D017706 @@@lisinopril@@@) a normalized extracellular matrix, a reduced expression of genes involved in @DISEASE_Carcinoma_Pancreatic_Ductal @DISEASE_MESH:D021441 @@@PDAC@@@ progression (e.g., WNT and Notch signaling), and an increased expression of genes linked with the activity of T cells and antigen-presenting cells. ", "citations": {"NLM": "Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A, Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemoe KD, Fernandez-Del Castillo C, Downes M, Evans RM, Michaelson J, Ferrone CR, Boucher Y, Jain RK. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Oct 1;23(19):5959-5969. PMID: 28600474", "BibTeX": "@article{28600474, title={Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.}, author={Liu H and Naxerova K and Pinter M and Incio J and Lee H and Shigeta K and Ho WW and Crain JA and Jacobson A and Michelakos T and Dias-Santos D and Zanconato A and Hong TS and Clark JW and Murphy JE and Ryan DP and Deshpande V and Lillemoe KD and Fernandez-Del Castillo C and Downes M and Evans RM and Michaelson J and Ferrone CR and Boucher Y and Jain RK}, journal={Clin Cancer Res}, volume={23}, number={19}, pages={5959-5969}}"}}]}